| Susan J Webb, CRNA | |
|
1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 | |
| (734) 936-4000 | |
| Not Available |
| Full Name | Susan J Webb |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 21 Years |
| Location | 1500 E Medical Center Dr, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548288053 | NPI | - | NPPES |
| 4559255 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 4704143376 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Michigan Health System | Ann arbor, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of Michigan | 3779496856 | 2953 |
News Archive
A person is considered a cancer survivor from the minute they are diagnosed with the disease. Tips from experts at the University of Alabama at Birmingham (UAB) can help survivors continue pre-diagnosis daily routines that may include working; one such expert, a cancer survivor herself, experienced firsthand the benefits and challenges of survivorship in the workplace.
Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.
An NIH-sponsored, multi-year study of hundreds of women diagnosed with breast cancer found that Positron Emission Mammography (PEM) scanners significantly outperform MRI when differentiating between benign and cancerous lesions.
Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.
The Wall Street Journal: "Republicans in Congress are taking aim at AARP's financial ties to the health-insurance industry just as the advocacy group is taking a more prominent role supporting an overhaul of the nation's health-care system."
› Verified 5 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528010428 PECOS PAC ID: 3779496856 Enrollment ID: O20031121000336 |
News Archive
A person is considered a cancer survivor from the minute they are diagnosed with the disease. Tips from experts at the University of Alabama at Birmingham (UAB) can help survivors continue pre-diagnosis daily routines that may include working; one such expert, a cancer survivor herself, experienced firsthand the benefits and challenges of survivorship in the workplace.
Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.
An NIH-sponsored, multi-year study of hundreds of women diagnosed with breast cancer found that Positron Emission Mammography (PEM) scanners significantly outperform MRI when differentiating between benign and cancerous lesions.
Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.
The Wall Street Journal: "Republicans in Congress are taking aim at AARP's financial ties to the health-insurance industry just as the advocacy group is taking a more prominent role supporting an overhaul of the nation's health-care system."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susan J Webb, CRNA 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | Susan J Webb, CRNA 1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 Ph: (734) 936-4000 |
News Archive
A person is considered a cancer survivor from the minute they are diagnosed with the disease. Tips from experts at the University of Alabama at Birmingham (UAB) can help survivors continue pre-diagnosis daily routines that may include working; one such expert, a cancer survivor herself, experienced firsthand the benefits and challenges of survivorship in the workplace.
Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.
An NIH-sponsored, multi-year study of hundreds of women diagnosed with breast cancer found that Positron Emission Mammography (PEM) scanners significantly outperform MRI when differentiating between benign and cancerous lesions.
Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.
The Wall Street Journal: "Republicans in Congress are taking aim at AARP's financial ties to the health-insurance industry just as the advocacy group is taking a more prominent role supporting an overhaul of the nation's health-care system."
› Verified 5 days ago
Denise Lynn Berry, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Ashley Marie Dibardino, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Terrance Solan, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Paula K Globerson, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1500 East Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4280 | |
Lawrence R Stump, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4280 | |
Mary Catherine Downey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Renee Ann Shea, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Drive, 1h247 University Hospital, Ann Arbor, MI 48109 Phone: 734-936-4280 |